# US 8,278,339 B2 · Valsartan salts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,339 B2
- Document ID: US8278339B2
- Status: Granted
- Kind: B2
- Application number: 12/186,172
- Filed: 2008-08-05
- Published: 2008-11-27
- Granted: 2012-10-02
- Earliest claimed: 2000-07-19
- Assignees: Novartis AG
- Inventors: Erwin Marti; Hans R Oswald; Peter Bühlmayer; Wolfgang Marterer
- Web page: https://patentgrep.com/patent/US8278339B2

## CPC

- C07D 257/04: Five-membered rings
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.

## Claims

### Claim 1

A calcium salt of valsartan in a crystalline, partially crystalline or an amorphous form.

### Claim 2 (depends on 1)

The calcium salt of valsartan according to claim 1 as a tetrahydrate.

### Claim 3 (depends on 2)

The tetrahydrate according to claim 2, characterised by
(i) an X-ray powder pattern taken with a Guinier camera comprising the following interlattice plane intervals: d in [Å]: 16.1±0.3, 9.9±0.2, 9.4±0.2, 7.03±0.1, 6.50±0.1, 5.87±0.05, 5.74±0.05, 4.95±0.05, 4.73±0.05, 4.33±0.05, 4.15±0.05, 4.12±0.05, 3.95±0.05; or
(ii) an ATR-IR spectrum having the following absorption bands expressed in reciprocal wavenumbers (cm−1): 1621(st), 1578(m), 1458(m), 1441(m), 1364(m), 1012(m), 758(m), 738(m), 696(m), 666(m).

### Claim 4 (depends on 1)

A salt according to claim 1 in the form of a solvate.

### Claim 5 (depends on 1)

A salt according to claim 1 in the form of a hydrate.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising a a calcium salt of valsartan according to claim 1 and a pharmaceutically acceptable excipient or additive.

### Claim 7 (depends on 6)

A pharmaceutical composition according to claim 6, in combination with at least one composition selected from the group consisting of:
(i) HMG-Co-A reductase inhibitor or a pharmaceutically salt thereof,
(ii) angiotensin converting enzyme (ACE) inhibitor or a pharmaceutically acceptable salt thereof,
(iii) calcium channel blacker or a pharmaceutically acceptable salt thereof,
(iv) aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof,
(v) aldosterone antagonist or a pharmaceutically acceptable salt thereof,
(vi) dual angiotensin converting enzyme/neutral endopeptidase (ACE/NEP) inhibitor or a pharmaceutically acceptable salt thereof,
(vii) endothelin antagonist or a pharmaceutically acceptable salt thereof,
(viii) renin inhibitor or a pharmaceutically acceptable salt thereof, and
(ix) diuretic or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

A method for the treatment of diseases and conditions which can be inhibited by blocking the AT1 receptor comprising administering a therapeutically effective amount of the calcium salt of valsartan of claim 1 to a patient in need thereof.
